lorlatinib
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
A significant subset of patients with non–small-cell lung cancer (NSCLC) harbor activating mutations in key oncogenes like EGFR…
The tyrosine-kinase inhibitors (TKIs) crizotinib and entrectinib have been approved by the FDA for the treatment of ROS1-positive…
BACKGROUND: Lorlatinib is a selective, potent, brain-penetrant, 3rd-generation ALK/ROS1 TKI preclinically active against most…
In the last decade huge improvements in prognosis
and quality of life have been provided by the molecular
characterization of…
Patients with lung cancer who show EML4-ALK translocation are routinely treated with ALK tyrosine kinase inhibitors, although in…
Data from a phase I study indicate that the investigational ALK inhibitor lorlatinib is active in patients with ALK- or ROS1…
ALK-positive Anaplastic Large Cell Lymphoma (ALCL) represents a subset of Non-Hodgkin Lymphoma whose treatment benefited from…